Clinical trials: Pulmonary Hypertension
Pulmonary Arterial Hypertension
Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension
Patients with symptomatic idiopathic (IPAH) or familial (FPAH) pulmonary arterial hypertension in New York Heart Association (NYHA) class II to IV , naive to PAH treatment or currently being treated with a stable dose of either…
- Trial name
- PROWESS 15 Ext (NCT00709098)
- Testing
- iloprost
- Where
- 34 sites in United States, Austria and 1 more
- Volunteers
- 49 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Study of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension
Multi-center, double-blind, placebo-controlled, randomized, parallel study comparing continuous intravenous (IV) Remodulin® to placebo in patients with pulmonary arterial hypertension either primary (PPH) or associated with human…
- Trial name
- TRUST-1 (NCT00494533)
- Testing
- Remodulin (treprostinil sodium)
- Where
- 14 sites in India
- Volunteers
- 45 people
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
This study is designed to understand the relative bioavailability (proportion of the administered dose that is absorbed into the bloodstream) of several fixed dose combinations (FDCs) tablets of ambrisentan and tadalafil for…
- Trial name
- NCT02688387
- Testing
- FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose, Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)
- Where
- United Kingdom
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypertension, Pulmonary, Lung Diseases, Interstitial
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
A trial to evaluate the safety, tolerability, and functionality of 3P-100, in subjects with Pulmonary Hypertension (PH) accompanying Interstitial Lung Disease (ILD), PH-ILD
- Trial name
- EFS (NCT05867914)
- Testing
- Inhaled Nitric Oxide (iNO)
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Third Pole Therapeutics, Inc.
Pulmonary Arterial Hypertension
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
This study provided/continued to provide oral treprostinil (UT-15C SR; treprostinil diethanolamine) to eligible subjects who participated in Studies TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE-PH-308.
- Trial name
- FREEDOM-EXT (NCT01027949)
- Testing
- Oral Treprostinil
- Where
- 134 sites in United States, Australia and 18 more
- Volunteers
- 894 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension, Interstitial Lung Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
- Trial name
- PALM-ILD (NCT07179380)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 186 sites in United States, Argentina and 28 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Pulmonary Hypertension, Pulmonary Fibrosis
Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
This multicenter, randomized, open-label study will assess the safety and efficacy of oral treprostinil in subjects diagnosed with pulmonary hypertension associated with pulmonary fibrosis.
- Trial name
- NCT02603068
- Testing
- Oral treprostinil
- Where
- 7 sites in United States
- Sponsor
- United Therapeutics
Hypertension, Pulmonary
An Observational Study For Ambrisentan
The purpose of the programme is to collect safety data on ambrisentan when used in clinical practice
- Trial name
- VOLT (NCT00679224)
- Testing
- ambrisentan
- Where
- 112 sites in Australia, Belgium and 13 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Pulmonary Fibrosis, Pulmonary Hypertension
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled dose escalation study to assess the safety and efficacy of pulsed, inhaled nitric oxide (iNO) in subjects with pulmonary fibrosis on long term oxygen therapy.
- Trial name
- NCT05747508
- Testing
- INOpulse®, Long Term Follow Up
- Where
- 23 sites in United States
- Volunteers
- 85 people
- Sponsor
- Bellerophon
Hypertension, Pulmonary, Pulmonary Disease, Chronic Obstructive
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
This study is to demonstrate the safety, tolerability, pharmakokinetic and pharmacodynamic effect of a single oral dose of BAY63-2521 in patients with pulmonary hypertension due to chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00640315
- Testing
- Riociguat (Adempas, BAY63-2521) 1.0 mg, Riociguat (Adempas, BAY63-2521) 2.5 mg
- Where
- 7 sites in Germany
- Volunteers
- 23 people
- Sponsor
- Bayer
Pulmonary Hypertension
ARIES - Ambrisentan in Patients With Moderate to Severe Pulmonary Arterial Hypertension (PAH)
The primary objective is to determine the effect of ambrisentan on exercise capacity in subjects with PAH.
- Trial name
- NCT00091598
- Testing
- Ambrisentan
- Where
- 46 sites in United States, Australia and 1 more
- Volunteers
- 372 people
- Sponsor
- Gilead Sciences
Pulmonary Hypertension, Interstitial Lung Disease
Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease
This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil.
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Combined Pulmonary Fibrosis and Emphysema
- Trial name
- NCT05572996
- Testing
- Inhaled Treprostinil
- Sponsor
- Ferrer Internacional S.A.
Dementia, Parkinson Disease
Data Collection Study for the Spectrum Dynamics Multi-purpose CZT SPECT Camera
This study evaluates SPECT image data acquired from Spectrum Dynamics' multi-purpose CZT SPECT-CT camera. All subjects will undergo routine clinical Anger SPECT imaging and an additional SPECT acquisition on the CZT SPECT camera.
- Conditions
- Dementia, Parkinson Disease, Pulmonary Hypertension, Heart Diseases
- Trial name
- NCT03438123
- Testing
- CZT SPECT imaging
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Spectrum Dynamics
Pulmonary Arterial Hypertension
TReatment Of Pulmonary HYpertension 1 Study
The objective of this study is to assess the safety, performance and initial effectiveness of the TIVUS™ System when used for pulmonary artery denervation through subjective and objective change in clinical parameters and…
- Trial name
- TROPHY (NCT02516722)
- Testing
- Therapeutic Intra-Vascular UltraSound (TIVUS™) System
- Where
- 4 sites in Belgium, Israel and 1 more
- Volunteers
- 15 people
- Sponsor
- SoniVie Inc.
Hypertension, Pulmonary
Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)
To describe the prevalence, incidence and current treatment and procedures patterns in a US pediatric population with PAH in MarketScan database during the period 2010-2013
- Trial name
- NCT02576002
- Testing
- Assigned pulmonary hypertension medication
- Where
- United States
- Volunteers
- 2,691 people
- Sponsor
- Bayer
Hypertension, Pulmonary
Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor
BAY63-2521 Riociguat leads to the relaxation of smooth muscle cells in pulmonary arteria and may also inhibit abnormal remodeling of lung blood vessels.
- Trial name
- RESPITE (NCT02007629)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 27 sites in United States, Belgium and 7 more
- Volunteers
- 61 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)
This study will evaluate the safety, tolerability, and PK of MK-8892 in participants with pulmonary arterial hypertension. The primary hypothesis is that the geometric mean of MK-8892 area under the concentration time-curve from…
- Trial name
- NCT01926509
- Testing
- MK-8892
- Volunteers
- 23 people
- Sponsor
- Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
Drug Interaction Between Ritonavir And Sitaxsentan
The study is to assess if sitaxsentan and ritonavir will affect the blood levels of each other when coadministered.
- Trial name
- NCT01251848
- Testing
- Sitaxentan, Ritonavir, Sitaxsentan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Hypertension
Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients
Recently it has been shown that clear reproducible Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package parametric Doppler, TPD…
- Trial name
- NCT01913457
- Testing
- Ultrasound Doppler
- Where
- 2 sites in United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Echosense Ltd.
Pulmonary Arterial Hypertension
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
- Trial name
- NCT06274801
- Testing
- Seralutinib, Gereic Dry Powder Inhaler
- Where
- 120 sites in United States, Argentina and 28 more
- Volunteers
- 330 people
- Sponsor
- Gossamer Bio USA, Inc.